Analyses of five wild-type p53 containing cell lines revealed lineage specific differences in phosphorylation of Thr18 after treatment with ionizing (IR) or ultraviolet (UV) radiation. Importantly, Thr18 phosphorylation correlated with induction of the p53 downstream targets p21 Waf1/Cip1 (p21) and Mdm-2, suggesting a transactivation enhancing role. Thr18 phosphorylation has been shown to abolish side-chain hydrogen bonding between Thr18 and Asp21, an interaction necessary for stabilizing alpha -helical conformation within the transactivation domain. Mutagenesisderived hydrogen bond disruption attenuated the interaction of p53 with the transactivation repressor Mdm-2 but had no direct effect on the interaction of p53 with the basal transcription factor TAF II 31. However, prior incubation of p53 mutants with Mdm-2 modulated TAF II 31 interaction with p53, suggesting Mdm-2 blocks the accessibility of p53 to TAF II 31. Consistently, p53-null cells transfected with hydrogen bond disrupting p53 mutants demonstrated enhanced endogenous p21 expression, whereas p53/Mdm-2-double null cells exhibited no discernible differences in p21 expression. We conclude disruption of intramolecular hydrogen bonding between Thr18 and Asp21 enhances p53 transactivation by modulating Mdm-2 binding, facilitating TAF II 31 recruitment.
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Introduction
The tumor suppressor protein p53 is an important regulator of cell viability and genomic integrity. Wildtype p53 normally exists as a short-lived protein but is activated and stabilized in response to various forms of cellular stress resulting in cell cycle arrest or apoptosis (reviewed by Levine, 1997; Giaccia and Kastan, 1998; Prives, 1998; Vousden, 2000) . These responses prevent the replication of cells with damaged DNA, thereby protecting cells from accumulating potentially oncogenic genetic alterations, or act to eliminate cells dividing under abnormal conditions. P53 induces cell cycle arrest by acting as a sitespecific transcription factor for genes whose products are directly involved in arresting cell growth and proliferation (reviewed by Levine, 1997; Giaccia and Kastan, 1998; Prives, 1998) . Cell cycle arrest is regulated at least in part by increasing expression of p21 Waf1/Cip1 (p21), whose protein inhibits the activity of several Cyclin/Cdk complexes required for the transition from G 1 to S phase (El-Deiry, 1998) . The product of another p53-response gene, GADD45, is suggested to participate in p53-dependent G 2 arrest by inhibiting Cyclin B/Cdc-2 activation Zhan et al., 1999) . P53 may also regulate apoptosis by activating the expression of pro-apoptotic genes such as bax and fas/APO-1 (Miyashita and Reed, 1995; Owen-Schaub et al., 1995; El-Deiry, 1998) . Another specific target upregulated by p53 is the proto-oncogene mdm-2 ( Levine, 1997) , an attenuator of p53 function that is overexpressed in certain tumors (Jones et al., 1995) . These findings demonstrate the importance of p53s role as a transcription factor in its ability to suppress tumor development and growth.
The capacity of p53 to function as a transcription factor is orchestrated by four modular domains: the transcriptional activation domain (amino acids 1 -42), the sequence-specific DNA binding domain (amino acids 120 -290), the tetramerization domain (amino acids 324 -355) and the DNA binding regulatory domain (amino acids 370 -393) . The DNA binding domain is the predominant target for genetic mutations in human tumors, whereas the transactivation and DNA binding regulatory domains appear to be key targets of epigenetic alteration. These domains are also a link between p53 function and extracellular stimuli (reviewed by Levine, 1997; Prives, 1998) . A great deal of interest has focused on the transactivation domain, which is functionally deregulated in association with human tumorigenesis (Prives, 1998) . This domain serves to regulate the transcriptional activation (transactivation) function of p53 by interacting with members of the basal transcription machinery including the TATA-binding protein TBP (Seto et al., 1992; Chen et al., 1993; Liu et al., 1993; Mack et al., 1993; Martin et al., 1993; Truant et al., 1993) and the TBP associated factors TAF II 31 (Lu and Levine, 1995) , TAF II 40 and TAF II 60 (Thut et al., 1995; Farmer et al., 1996) . The transactivation domain also interacts with the CREB-binding protein (CBP) and p300 transcriptional co-activators Avantaggiati et al., 1997; Lill et al., 1997) , upregulating sequence-specific DNA binding by acetylating the DNA binding regulatory domain of p53 Scolnick et al., 1997; Sakaguchi et al., 1998; Liu et al., 1999) .
In addition to being a transcriptional target of p53, Mdm-2 forms a complex with p53, dependent on amino acids Ph19, Leu22 and Trp23 within the transactivation domain (Lin et al., 1994; Kussie et al., 1996) . Complex formation results in two characterized functional outcomes. First, Mdm-2 competes for the same hydrophobic residues within the transactivation domain that directly interact with TAF II 31 (Lu and Levine, 1995) , TAF II 40 and TAF II 60 (Thut et al., 1995; Farmer et al., 1996) . Thus, Mdm-2 acts as a negative regulator for p53s transactivation function in vivo (Oliner et al., 1993; Wu et al., 1993; Jimenez et al., 2000) . Secondly, Mdm-2 functions as a nuclearcytoplasmic shuttle of p53 (Roth et al., 1998; Tao and Levine, 1999a,b) . This process plays a significant role in the Mdm-2 mediated degradation of p53 by the ubiquitin-dependent 26S proteosome (Haupt et al., 1997; Kubbutat et al., 1997) , of which Mdm-2 acts as an E3 ubiquitin ligase (Honda et al., 1997; Feng et al., 2000) . However, the impact of Mdm-2/p53 complex formation on p53 degradation is affected by other factors in the cell. The interaction of the Mdm-2/p53 complex with p300 has been shown to promote p53 degradation (Grossman et al., 1998) , whereas the interaction of the Mdm-2/p53 complex with Rb, Abl or ARF has been shown to stabilize p53 (Hsieh et al., 1999; Sionov et al., 1999; Zhang and Xiong, 1999) .
The transactivation domain has been shown to be a rich spot for regulation by phosphorylation. DNA damage caused by treatment with ionizing radiation (IR) or ultraviolet radiation (UV) has been reported to result in the de novo phosphorylation of p53 within the transactivation domain at Ser6 , Ser9 , Ser15 (Siliciano et al., 1997; Shieh et al., 1997) , Thr18 Sakaguchi et al., 2000;  this manuscript), Ser20 (Chehab et al., 1999; Unger et al., 1999a; Jabbur et al., 2000) , Ser33 and Ser37 Sakaguchi et al., 1998) . In vitro experiments attribute these events to cellular kinases, including CKI Sakaguchi et al., 2000; Higashimoto et al., 2000) , p38 MAPK (Bulavin et al., 1999) , ATM (Banin et al., 1998; Canman et al., 1998) , ATR (Tibbetts et al., 1999) , DNA-PK (Woo et al., 1998) , Cds1/Chk2 (Shieh et al., 2000) , Chk1 (Chehab et al., 2000; Hirao et al., 2000; Shieh et al., 2000) , JNK1 (Milne et al., 1995) and CAK (Ko et al., 1997) .
The role of phosphorylation within the transactivation domain of p53 is beginning to be illustrated. The phosphorylation of p53 at Ser15, Ser33 and Ser37 enhances the recruitment of p300 and CBP (Lambert et al., 1998; Sakaguchi et al., 1998) , whereas phosphorylation at Ser15, Ser20 and Ser37 disrupts the interaction of p53 with Mdm-2 Chehab et al., 1999; Unger et al., 1999a; Jabbur et al., 2001) . In addition, the phosphorylation of p53 at Ser15, Ser20 and Ser37 modulates the transactivation function of p53 Jabbur et al., 2000 Jabbur et al., , 2001 , whereas Ser20 and Ser33 phosphorylation affects apoptotic function in a cell-type specific manner (Bulavin et al., 1999; Unger et al., 1999a,b) . Hence, the stress-induced phosphorylation of p53 within the transactivation domain bestows p53 with transactivation attributes consistent with its ability to repel Mdm-2 and to interact with p300 and CBP.
Crystallographic analysis of the transactivation domain of p53 has illustrated residues 18 through 27 arranged in an alpha helical structure (Kussie et al., 1996) , necessary for the interaction of p53 with Mdm-2 and TAF II 31 (Kussie et al., 1996; Uesugi and Verdine, 1999) . Structural integrity is maintained in part by intramolecular hydrogen bonds formed by the side chains of the amino acids Thr18 and Asp21 (Kussie et al., 1996; Uesugi and Verdine, 1999) . We hypothesize this interaction is abridged by the phosphorylation of p53 at Thr18, thereby altering the amphipathic a-helix and changing the conformation of the hydrophobic binding cleft. Hence, we examined the incidence of irradiation induced Thr18 phosphorylation and the effect of disrupting intramolecular hydrogen bonding between Thr18 and Asp21 on the interaction of p53 with Mdm-2 and TAF II 31, and on the ability of p53 to transactivate target gene expression.
Results
To demonstrate the in vivo phosphorylation states of p53 at Thr18, a 10-amino-acid p53 peptide containing phosphorylated Thr at amino acid 18 ( Figure 1a ) was used to generate a polyclonal antibody (PAbThr18P). PAbThr18P exhibited specific recognition for dotblotted Thr18-phosphorylated p53 peptide ( Figure  1b ). This recognition was abolished upon competition with Thr18-phosphorylated peptide, but not upon competition with Thr18 peptide (Figure 1c ). In addition, PAbThr18P antibody did not cross-react with phosphorylated or non-phosphorylated Ser15 and Ser20 peptides, as well as two randomly generated peptides containing phosphorylated Ser or Thr residues (Figure 1d ), indicating that PAbThr18P is specific for p53 peptide phosphorylated at Thr18 in vitro.
Treatment of cells with ionizing radiation (IR), which causes single-and double-strand DNA breaks (Collins, 1987) , results in enhanced p53 stability and site-specific phosphorylation at several sites (reviewed by Levine, 1997; Giaccia and Kastan, 1998; Prives, 1998) including Thr18 in A549 lung carcinoma cells . To demonstrate that our PAbThr18P antibody is capable of specifically recognizing p53 protein phosphorylated at Thr18 in vivo, wild-type (wt) p53 containing A549 cells were treated with IR or the proteosome/calpain inhibitor N-AcetylLeu-Leu-Norleucinal (ALLN), which has been shown to stabilize the p53 protein without inducing Ser15, Thr18 or Ser20 phosphorylation . In addition, p53 null K562 erythroleukemia cells were treated with IR after being transfected by electroporation with expression vectors for wt p53 or a p53 mutant harboring a Thr to Ala substitution at amino acid 18 (p53T18A). Total protein extract was isolated from non-treated (C) or treated A549 cells and transfected K562 cells post-treatment, immunoprecipitated for p53 protein and analysed by Western blotting for p53 phosphorylated at Thr18 by PAbThr18P antibody. The expression of total p53 protein was analysed by DO1 or PAb1801 antibody.
As shown in Figure 2a , endogenous p53 protein accumulated rapidly (within 2 h) in A549 cells after treatment with IR or ALLN as assayed by DO1 antibody. PAbThr18P antibody recognized p53 protein isolated from irradiated A549 cells. This recognition was abolished in the presence of Thr18-phosphorylated peptide competitor, but not when assaying in the presence of the unphosphorylated Thr18 peptide. In addition, phosphatase pre-treated p53 isolated from IR treated A549 cells, or p53 stabilized by treating A549 cells with ALLN, was not recognized by PAbThr18P antibody. Notably, the IR-treated fraction without phosphatase treatment exhibited a slower rate of migration than its phosphatase treated counterpart, presumably due to additional irradiation-induced phosphorylation events occurring on other residues.
Transient transfection with CMV-driven wt p53 and p53T18A vectors produced abundant levels of p53 protein, but no further stabilization and increased accumulation was detected after IR (Figure 2b ), Figure 2 PAbThr18P antibody specifically recognizes p53 protein phosphorylated at Thr18 in vivo. (a) Endogenous p53 protein is phosphorylated at Thr18 in response to treatment with ionizing radiation. A549 cells (p53 wt) were treated with IR or the proteosome/calpain inhibitor N-Acetyl-Leu-Leu-Norleucinal (ALLN). After treatment, total protein was extracted from treated cells or control cells under non-reducing conditions. P53 protein from the same amount of total protein or fivefold increment protein lysate ( 5x ) was immunoprecipitated (IP). Following centrifugation and wash, the precipitates were eluted in non-reducing sample buffer or treated with phosphatase (and subsequently eluted), fractionated by SDS -PAGE and subjected to Western blot analysis with PAbThr18P antibody in the presence or absence of competing peptide, or DO1 antibody for total p53 protein. (b) Transiently transfected p53 protein is phosphorylated at Thr18 in response to treatment with ionizing radiation. K562 cells (p53 null) were transfected with human p53 expression plasmid DNA encoding CMV (vector alone), wt p53 or p53T18A. Cells were irradiated and total protein was extracted from treated cells or control cells under non-reducing conditions and immunoprecipitated. Precipitates were eluted in non-reducing sample buffer and fractionated by SDS -PAGE, greatly overloading p53T18A relative to wt p53. Western blot analysis employed PAbThr18P antibody or 1801 antibody for total p53 protein probably due to maximal expression mediated by the expression vector and stabilization of p53 triggered by the transfection process itself. P53 isolated from nontreated or IR-treated wt p53 transfected K562 cells was similarly recognized by PAbThr18P. Replacement of Thr18 with Ala abolished recognition by PAbThr18 antibody. The presence of Thr18 phosphorylation in non-irradiated wt p53 transfected K562 cells may have been due to induced phosphorylation caused by the electroporation procedure or by DNA strand breaks present in the transfected DNA, as was also observed in p53 transfected H1299 lung carcinoma cells . These experiments demonstrated that PAbThr18P antibody specifically recognized the in vivo phosphorylation of p53 at Thr18 and affirms the reports using an independently produced antibody that p53 protein is phosphorylated at Thr18 in A549 cells in response to treatment with IR.
To investigate whether the induced phosphorylation of p53 at Thr18 occurs in response to treatment with ultraviolet radiation (UV) as well as IR and whether this is a common event among cells of different lineages, wt p53-containing BV173 chronic myelogenous leukemia, ML-1 myeloid leukemia, MCF7 breast carcinoma, LNCaP prostate carcinoma and A549 lung carcinoma cells were treated with IR or UV. The treatment of cells with UV causes T-T dimerization in DNA (Drouin and Therrien, 1997), resulting in enhanced p53 stability and site-specific phosphorylation (reviewed by Levine, 1997; Giaccia and Kastan, 1998; Prives, 1998) . After irradiation, p53 was immunoprecipitated from total protein extracts isolated from non-treated (C) and IR-or UV-treated cells at 6 and 12 h post-treatment, respectively, and analysed for the phosphorylation of Thr18 by PAbThr18P antibody or total p53 protein by DO1 antibody on a Western blot. The presence of wt p53 in these cell lines also allowed us to evaluate the impact of Thr18 phosphorylation on the transactivation function of p53, as assessed by Western blot analysis of the expression levels of p21 Waf1/Cip1 (p21) and Mdm-2 protein.
As shown in Figure 3b , endogenous p53 protein was stabilized in each cell line in response to treatment with IR and UV. A strong induction of p21 and Mdm-2 protein expression was also elicited in each cell line in response to treatment with IR. However, the induction of p21 and Mdm-2 expression by UV occurred only in LNCaP, MCF7 and A549 cells; p21 and Mdm-2 expression, and p21 mRNA expression (data not shown) was not observed in BV173 or ML-1 cells subjected to treatment with UV. Importantly, the phosphorylation of p53 at Thr18 correlated with the induction of p21 and Mdm-2 expression in each cell line ( Figure 3a ) as well as p21 expression in BV173 and ML-1 cells. These observations were consistent with those of earlier time points following irradiation (0.5, 1.0, 2.0, 3.0 h), ruling out the possibility of cell-type specific differences in the kinetics of induction (data not shown).
Our findings demonstrated that phosphorylation of p53 at Thr18 was not required for p53 stabilization in UV-treated BV173 and ML-1 cells. Moreover, the induction of p21 by IR, but not by UV, in BV173 and ML-1 cells suggested that phosphorylation of p53 at Thr18 may enhance p53s transactivation function. Accumulation of the p53 protein in response to treatment with UV was not sufficient to effectively activate p21 and Mdm-2 expression in the absence of marked phosphorylation at Thr18, suggesting a general physiological role for Thr18 phosphorylation on p53 in response to genotoxic stress caused by irradiation. These findings raised the question of how the transactivation domain of p53 could be altered by phosphorylation at Thr18.
Thr18 is located in a short peptide segment of the p53 transactivation domain that interacts with the negative and positive regulators of p53, Mdm-2 and TAF II 31. In the crystal structure of the Mdm-2/p53 complex (Kussie et al., 1996) , this short segment (residues 18 to 27) forms an amphipathic a-helix. The hydrophobic face of the p53 helix packs against a hydrophobic pocket on Mdm-2 with a triad of hydrophobic and aromatic residues, Phe19, Trp23, and Leu26, inserting deep into the Mdm-2 cleft ( Figure  4a , 5a). Thr18 on the polar or charged face of the p53 helix appears to stabilize the newly formed helix by a network of intramolecular hydrogen bonding interactions. The side-chain hydroxyl group of Thr18 hydrogen bonds with the backbone amide and sidechain carboxyl group of Asp21, and the Thr18 backbone amide hydrogen bonds with the Asp21 carboxyl group (Kussie et al., 1996) . Phosphorylation of Thr18 introduces an additional negative charge between Thr18 and Asp21 and almost certainly disrupts the helix-initiating hydrogen bonds between these two residues through charge -charge repulsion. Thus, the phosphorylation of Thr18 would be energetically unfavorable for the interaction of p53 with Mdm-2. We tested this model by generating three classes of point mutants of the p53 transactivation domain. The first class of mutants contained substitution of Thr18 with a negatively charged, phosphorylation-mimicking amino acid, Asp (p53T18D). This mutant was expected to exert a potent effect on the interaction of p53 with Mdm-2. The second class of mutant contained substitution of Thr18 or Asp21 with noncharged Ala (p53T18A and p53D21A). As suggested by the results from molecular modeling assays, these two mutants did not form side-chain hydrogen bonds, interactions stabilizing the particular a-helical structure of the p53 transactivation domain bound to Mdm-2 (Figure 4b,c) . The third class of mutants contained substitution of Asp21 with an Asn (p53D21N). In this mutant, the critical hydrogen bond formed between the side chain of residues 18 and 21 was maintained (Figure 4d ).
We first evaluated the effects of these mutations on the interaction of p53 with Mdm-2 in vitro. GST fusions of wt and p53 mutants were incubated with full-length, in vitro translated, 35 S-labeled Mdm-2. As shown in Figure 5b , the negative control GST and GST -p53 1-52 L22Q/W23S had no detectable affinity to interact with Mdm-2. Replacement of Leu22 and Trp23 with Gln and Ser has been shown to ablate the interaction of p53 with Mdm-2 (Lin et al., 1994) . GST -wt 1-52 p53 tightly bound Mdm-2 as reported (Uesugi and Verdine, 1999) . GST -p53 fusion proteins containing amino acid substitutions at Thr18 or Asp21 exhibited distinct abilities to pull-down Mdm-2. Hydrogen bond retaining GST -p53 1-52 D21N bound Mdm-2 (109%+19%) as tightly as GST -wt 1-52 p53 (100%+8%), whereas hydrogen bond-disrupting GST -p53 1-52 T18A (65%+4%), GST -p53 1-52 D21A (47%+12%) and GST -p53 1-52 T18D (26%+4%) demonstrated lower abilities to pull-down Mdm-2. These results are consistent with our prediction that disruption of the hydrogen bond between Thr18 and Asp21 reduces the interaction of p53 with Mdm-2.
Next, we investigated the impact of hydrogen bond disruption between Thr18 and Asp21 on the interaction of p53 with TAF II 31, a co-activator of p53 whose binding site overlaps that of Mdm-2. GST fusions of the wt and p53 mutants were incubated with a purified N-terminal 140 amino acid fragment of TAF II 31 (TAF II 31 ). This fragment of TAF II 31 has been shown sufficient for binding to the transactivation domain of p53 (Uesugi and Verdine, 1999) . In a manner similar to the interaction with Mdm-2, GST and GST -p53 1-52 L22Q/W23S had no detectable affinity to TAF II 31 1-140 , whereas GST -wt 1-52 p53 bound TAF II 31 (Figure 5c ). In contrast to the observed interaction with Mdm-2, however, GSTp53 fusion proteins containing hydrogen bond-disrupting (GST -p53 1-52 T18A (102%+11%); GST -p53 1-52 D21A (108%+11%); GST -p53 1-52 T18D (107%+ 1%)) or a hydrogen bond-retaining substitution (GST -p53 1-52 D21N (110%+5%)) demonstrated similar abilities to pull-down TAF II 31 1-140 as wt p53 (GST -wt 1-52 p53 (100%+11%)) ( Figure 5c ). Thus, the disruption of hydrogen bonding between Thr18 and Asp21 does not directly alter the interaction of p53 with TAF II 31. This observation is consistent with a recent report showing that TAF II 31 recognizes divergent sequences in transactivation domains (Choi et al., 2000) .
Since the interaction of TAF II 31 with p53 was unperturbed by disruption of the hydrogen bonds between Thr18 and Asp21, we explored if the reduced interaction of p53 with Mdm-2 mediated by hydrogen bond disruption is central to the recruitment of TAF II 31 to p53. We envisioned that binding of Mdm-2 blocks p53 from binding to TAF II 31. Thus, reduced binding to Mdm-2 would lead to increased binding to TAF II 31. To test this possibility we analysed the ability of the p53 mutants to pull-down TAF II 31 1-140 following prior incubation with Mdm-2. The results showed that with prior incubation of p53 with Mdm-2, the strong Mdm-2 binding proteins GST -p53 1-52 D21N (21%+5%) and GST -wt 1-52 p53 (20%+4%) exhibited the lowest abilities to pull-down TAF II 31 1-140 , whereas the weaker Mdm-2 binding proteins GST -p53 1-52 T18A (30%+6%) and GST -p53 1-52 D21A (32%+ 6%) demonstrated slightly higher abilities to pull-down TAF II 31 (Figure 5d) . Importantly, the weakest Mdm-2 binding protein GST -p53 1-52 T18D (75%+ 6%) demonstrated a very high ability to pull-down TAF II 31 1-140 . These results suggest that the recruitment of TAF II 31 to p53 is controlled by the regulated interaction of p53 with Mdm-2.
Our observations concerning the enhanced recruitment of the basal transcription factor TAF II 31 with p53 mutants containing disrupted hydrogen bonding between the residues Thr18 and Asp21 suggested a Figure 3 The stress-induced phosphorylation of p53 at Thr18 correlates with p21 and Mdm-2 induction in vivo. (a) Thr18 phosphorylation is cell lineage specific in response to treatment with ionizing or ultraviolet radiation. BV173 and ML-1 leukemia, and LNCaP, MCF7 and A549 carcinoma cells, all containing endogenous wt p53, were treated with IR or UV. After treatment, total protein was extracted from treated cells or control cells under non-reducing conditions. P53 protein was immunoprecipitated from the same amount of total protein. Following centrifugation and wash, the precipitates were eluted in non-reducing sample buffer or treated with phosphatase (and subsequently eluted), fractionated by SDS -PAGE and subjected to Western blot analysis with PAbThr18P antibody or DO1 antibody for total p53 protein. (b) Endogenous p21 and Mdm-2 expression correlates with Thr18 phosphorylation in response to treatment with ionizing or ultraviolet radiation. After treatment of BV173, ML-1, LNCaP, MCF7 and A549 cells, total protein was extracted from treated cells or control cells, fractionated by SDS -PAGE and analysed for the expression of p21 or Mdm-2 protein possible role in modulating the transcriptional activity of the p53 protein. To assess the transactivation potential of the p53 mutants, K562 erythroleukemia cells (p53 null) were transfected in a series with increasing amounts of expression vectors for full-length wt p53 or p53 mutants. Following transfection, total protein extract was isolated from transfected K562 cells and analysed by Western blotting for the expression of total p53 protein and p21 protein.
As shown in Figure 6a , transfection with the parental vector pCMV-Neo (CMV) did not induce the expression of p21, ruling out the possibility of p53-independent p21 induction caused by cell stress during the electroporation procedure. Moreover, all of the transfected p53 mutants, except for the transcriptionally deficient mutant p53L22Q/W23S (Jimenez et al., 2000) (Figure 6b ), induced endogenous p21 protein expression, indicating that the phosphorylation of p53 Figure 4 Hydrogen bond interaction between wild-type or mutagenized p53 residues at 18 or 21 is predicted using molecular modeling. (a) Wild-type (wt), (b) Ala18 (p53T18A), (c) Ala21 (p53D21A), or (d) Asn21 (p53D21N) p53 peptides (residues 17 through 29; turquoise color) are shown in three-dimensional association with Mdm-2 (residues 17 -125; pink color). Hydrophobic and aromatic p53 residues inserting into the Mdm-2 cleft are indicated (Phe19, Trp23 and Leu26; green color), as are the side chains of residues 18 (blue color) and 21 (red color). Predicted hydrogen bond interactions formed between the side chains of amino acid residues 18 and 21 are denoted in (a) and (d) by a dashed line. The images were modeled, drawn and rendered as described in experimental procedures at Thr18 is not mandatory for p53s transactivating function. However, the transactivation competent mutants induced p21 expression to different extents. To accurately quantify the transactivation activities of the p53 phosphorylation mutants, the expression of transfected p53 protein was plotted versus the expression of endogenous p21 protein on the x-and yordinates respectively for each transfected sample. Each transfection series was analysed by linear regression (Figure 6a) , from which the fold induction of endogenous p21 protein in p53 mutant-transfected cells, relative to wt p53-transfected cells, was calculated and graphed (Figure 6d ; black colored bars). The normalized results showed that the hydrogen bond disrupting p53 mutants p53T18A (2.0-fold) and p53D21A (3.8-fold) enhanced p21 expression compared with the level induced by wt p53 (1.0-fold), whereas the hydrogen bond retaining mutant p53D21N (1.0-fold) Figure 5 Mdm-2 blocks recruitment of TAF II 31 to the transactivation domain of p53. (a) p53 amino acid sequence of residues 1 -52, a-helical structure of residues 18 -27 and helical wheel presentation of residues 18 -24. The location of the a-helical structure within the transactivation domain primary sequence is denoted (rectangular box), as are the hydrophobic residues that are critical for p53 transcriptional activation (underline, a-helical structure; rectangular box, helical wheel presentation). (b) Disruption of hydrogen bonding between the p53 residues Thr18 and Asp21 reduces the interaction with Mdm-2. GST, GST-p53 1-52 wt or mutant proteins (as indicated) were incubated in vitro with full-length 35 S-labeled Mdm-2. After centrifugation and wash, the precipitates were eluted, fractionated by SDS -PAGE and resolved by autoradiography. Mdm-2 bands were quantified and the relative pulldown of Mdm-2 by p53 was tabulated from the average of three replicate experiments. (c) TAF II 31 interaction is unaffected by the disruption of hydrogen bonding between the p53 residues Thr18 and Asp21. GST, GST-p53 1-52 wt or mutant proteins (as indicated) were incubated in vitro with TAF II 31 1-140 . After centrifugation and wash, the precipitates were eluted, fractionated by SDS -PAGE and revealed by Coomassie stain. TAF II 31 1-140 bands were quantified; the relative pull-down of TAF II 31 1-140 by p53 was tabulated from the average of three replicate experiments. (d) The reduced interaction of p53 with Mdm-2 facilitates TAF II 31 binding to p53. GST-p53 1-52 wt or mutant proteins (as indicated) were incubated in vitro with full-length 35 S-labeled Mdm-2 prior to incubation with TAF II 31 1-140 . After centrifugation and wash, the precipitates were eluted, fractionated by SDS -PAGE and revealed by Coomassie stain. TAF II 31 1-140 bands were quantified; the relative pull-down of TAF II 31 1-140 by p53 was tabulated from the average of three replicate experiments had the same ability to induce p21 compared with the level induced by wt p53. In contrast, the phosphorylation-mimicking mutant p53T18D (6.1-fold) enhanced p21 expression the strongest.
To verify that the differences in p53 hydrogen bond mutant induction of p21 occurs at the transcriptional level, total RNA was isolated from transfected K562 cells and analysed for p21 expression by Northern blot, using a radiolabeled p21 cDNA probe. Equivalent amounts of assayed total RNA were verified by ethidium bromide staining of the formaldehyde-agarose gel and analysis of 28S/18S rRNA (Figure 6c ). Each transfected sample expressed equivalent amounts of transfected wt and mutant p53 protein, as assessed by Western blotting using PAb1801 antibody (data not shown). As observed for p21 protein expression by Western blotting in Figure 6a , transfection with CMV did not induce the expression of p21 mRNA ( Figure  6c) . Consistently, the expression of p21 mRNA induced by the hydrogen bond-disrupting p53 mutants p53T18A (2.8-fold) and p53D21A (3.8-fold), the phosphorylation-mimicking mutant p53T18D (7.7-fold), the hydrogen bond-retaining mutant p53D21N (1.2-fold), and wt p53 (1.0-fold) closely correlated with Figure 6 The transactivation of endogenous p21 is enhanced by hydrogen bond disruption between the p53 residues Thr18 and Asp21. (a,b) Western blot analysis of p21 protein expression. K562 cells (p53 null) were transfected with human p53 expression plasmid DNA encoding CMV (vector alone), wt p53, or p53 mutants (as indicated). Twenty-four hours after transfection, total protein was extracted, fractionated by SDS -PAGE and analysed for the expression of p53, actin and p21. The expression of transfected p53 protein (x-ordinate) versus the expression of endogenous p21 protein (y-ordinate) was plotted for each transfected sample (wt p53, shaded diamond; p53T18A (Ala18), open box; p53T18D (Asp18), open triangle; p53D21A (Ala21), shaded box; p53D21N (Asn21), shaded triangle). Each transfected series was subjected to analysis by simple linear regression, from which the fold induction of endogenous p21 protein in p53T18A-, p53T18D-, p53D21A-or p53D21N-transfected cells, relative to wt p53-transfected cells (set to onefold), was calculated and indicated. (c) Northern blot analysis of p21 mRNA expression. Total RNA was extracted from transfected K562 cells and the expression of p21 mRNA was analysed by Northern blotting. p21 expression was quantified by PhosphorImager, and p21 mRNA levels were normalized to that of 28S rRNA. The ratio of p21 to 28S rRNA for wt p53-transfected cells was designated as 1 and the fold of endogenous p21 induction in P53T18A-, p53T18D-, p53D21A-or p53D21N-transfected cells was indicated under each lane from the average of two replicate experiments. (d) Tabular representation of p21 protein (black colored bar) or mRNA (gray colored bar) induction the induction of p21 protein (Figure 6d ). These results suggest that disruption of the hydrogen bond between Thr18 and Asp21 promotes the ability of p53 to transactivate p21.
To further our understanding of the influence of Mdm-2 on p53 transactivation in response to hydrogen bond disruption between the p53 residues Thr18 and Asp21, we examined the transactivation potential for p21 mediated by wt p53 and hydrogen bond disrupting or retaining p53 mutants in the p53/Mdm-2 double-null cell line 2KO (de Oca Luna et al., 1995) . 2KO mouse fibroblasts were transfected with CMV, wt p53 or p53 mutants. Following transfection, total protein extract was isolated from transfected 2KO cells and analysed by Western blotting for the expression of total p53 protein and p21 protein.
As shown in Figure 7 , transfection with CMV did not induce the expression of p21 protein, as verified by the observation that similar levels of p21 were expressed in non-transfected 2KO cell total protein extracts isolated (data not shown). This finding rules out the possibility of p21 induction caused by cell stress during the transfection procedure. Equivalent amounts of total protein were assayed, as verified by tubulin protein expression. In addition, each transfected sample expressed equivalent amounts of transfected wt and mutant p53 protein. Significantly, all of the transfected p53 mutants, except for the transcriptionally deficient mutant p53L22Q/W23S, induced endogenous p21 protein expression to equivalent amounts in the absence of endogenous Mdm-2. These results suggest that phosphorylation-induced disruption of the hydrogen bond between Thr18 and Asp21 promotes the ability of p53 to transactivate p21 by inhibiting the interaction of p53 with Mdm-2, facilitating the interaction of p53 with TAF II 31, which positively influences the transactivation function of p53.
Discussion
In vitro and in vivo studies have demonstrated the importance of Mdm-2 as a regulator of the homeostatic and functional attributes of p53. Indeed, the critical impact of the p53 protein on cell proliferation and apoptosis necessitates the presence of an equally potent regulator. Nowhere is this more evident than in studies performed using gene knockout technology in transgenic mice. In these experiments, mdm-2 null mice were found to possess en embryonic lethal phenotype that was rescued by the additional knockout of the p53 gene (de Oca Luna et al., 1995; Jones et al., 1995) , providing evidence that the primary defect in mdm-2 null mice was excessive p53 activity. Moreover, the basal status of p53 in normal cells has been demonstrated to be maintained by Mdm-2 targeted degradation (Haupt et al., 1997; Kubbutat et al., 1997) . Both of these studies emphatically illustrate the importance of Mdm-2/p53 interaction in vivo. However, understanding the regulation of this important interaction, the role of other p53 interacting proteins and the structural basis for these complex interactions necessitates further investigation.
The discoveries that phosphorylation of p53 at Thr18 disrupts Mdm-2 binding provided a gateway to understand this process. Residues 18 through 26 of the transactivation domain of p53 form an amphipathic ahelix whose hydrophobic face packs against a hydrophobic pocket on Mdm-2 (Kussie et al., 1996) . The opposite side of the a-helix contains a network of hydrogen bonds. Among them are the hydrogen bond interactions formed between the amino acid residues Thr18 and Asp21, key elements contributing to the initiation and maintenance of a-helical structure within the transactivation domain (Kussie et al., 1996) . Disruption of the specific interactions between Thr18 and Asp21 by phosphorylation at Thr18 leads to destabilization of the Mdm-2/p53 complex, subsequently upregulating p53 transactivation function. Indeed, the interaction of Mdm-2 with a p53 peptide phosphorylated at Thr18 is significantly reduced (Bottger et al., 1999; Craig et al., 1999; Lai et al., 2000) .
In this study, we observed that ionizing radiation (IR)-induced phosphorylation at Thr18 was accompanied by enhanced p21 and Mdm-2 expression in each of the five wild-type (wt) p53-containing cell lines examined (Figure 3) . Intriguingly, Thr18 phosphorylation occurred as a cell line-dependent response to treatment with ultraviolet radiation (UV). UV treatment failed to induce Thr18 phosphorylation in ML-1 and BV173 leukemia cells but strongly induced Thr18 phosphorylation in LnCAP, MCF7 and A549 carcinoma cells. These results suggest that IR-and UVtreatment utilize distinct signal transduction pathways leading to p53 modification at Thr18. Importantly, the status of Thr18 phosphorylation in UV-treated cells correlated with p21 and Mdm-2 induction, functionally linking Thr18 phosphorylation to p53 transactivation function in vivo. Figure 7 The abridged interaction of p53 with Mdm-2 is responsible for the enhanced transactivation of endogenous p21 mediated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. 2KO cells (p53/mdm-2 null) transfected with human p53 expression plasmid DNA encoding CMV (vector alone), wt p53, p53T18A, p53T18D, p53D21A, p53D21N, or p53L22Q/W23S. Twenty-four hours after transfection, total protein was extracted, fractionated by SDS -PAGE and analysed for the expression of p53, tubulin and p21
The phosphorylation of p53 at Thr18 is proposed to introduce two changes: to introduce negative charge and disrupt purported hydrogen bonds with Asp21. Thus, Thr18 phosphorylation ablates attractive forces caused by hydrogen bonding while concomitantly enhancing repulsive force through charge -charge repulsion. Conversely, when the dephosphorylation of Thr18 occurs, restoration of hydrogen bonding and ablation of charge -charge repulsion may contribute to the rapid stabilization of a particular a-helical conformation favoring interaction with Mdm-2. Sitedirected mutagenesis studies performed herein support the importance of charge -repulsive and hydrogen bond-attractive force modulation at Thr18 in regulating the interaction of p53 with Mdm-2 (Figure 5b ) and in regulating p53 transactivation function for p21. Specifically, the introduction of negative charge by substituting Thr18 with phosphorylation-mimicking Asp led to potent enhancement of p53 transactivation of p21 (Figure 6c ). Moreover, Ala substitution at Thr18 or Asp21 resulted in moderate enhancement of p53 transactivation of p21. In contrast, the substitution of Asp21 with Asn21, which is suggested to retain hydrogen bond character (Figure 4d ), did not affect p53 transactivation of p21 (Figure 6c ).
Our observation of p53 protein stabilization in the absence of Thr18 phosphorylation in UV-treated ML-1 and BV173 cells (Figure 3 ) supports the notion that Thr18 phosphorylation is not a critical modulator of p53 stability in vivo, although it has been demonstrated to weaken the interaction of p53 with Mdm-2 (Bottger et al., 1999; Craig et al., 1999; Lai et al., 2000) . Recent reports suggest the stabilization of p53 is a complex process involving numerous regions on the p53 and Mdm-2 proteins. Whereas binding by Mdm-2 has been shown to promote the degradation of p53 (Haupt et al., 1997; Kubbutat et al., 1997) , Mdm-2 binding and Mdm-2-mediated p53 degradation have been shown to be two separate events (Kubbutat et al., 1998; Jabbur et al., 2001) . Importantly, studies have implicated regions other than the transactivation domain of p53 (Kubbutat et al., 1998; Gu et al., 2000; Kwek et al., 2001 ) and regions of Mdm-2 (Mayo et al., 1997; Khosravi et al., 1999) to be required for the efficient degradation of p53. It is reasonable to consider that UV-treatment may induce modifications of other regions of p53 and/or Mdm-2, stabilizing the p53 protein in the absence of Thr18 phosphorylation. Hence, the interaction of Mdm-2 with p53 may result in two functional outcomes, affecting the transactivation function and stability of p53.
Note, the only other site phosphorylated in vivo within the amphipathic a-helix is Ser20 (Chehab et al., 1999; Shieh et al., 1999; Unger et al., 1999a; Jabbur et al., 2000) . Interestingly, Ser20 has a positively charged residue, Lys24, within proximity for potentially chargeattractive effects mediated by Ser20 phosphorylation. In vitro studies using phospho-Ser20 peptide and sitedirected mutagenesis analyses employing phosphorylation mimicking Asp or non-phosphorylation mimicking Ala mutants have shown that Ser20 phosphorylation attenuates Mdm-2 binding (Bottger et al., 1999; Chehab et al., 1999; Craig et al., 1999; Unger et al., 1999a; Jabbur et al., 2001; Lai et al., 2000) . The fact that both Ser20 and Thr18 are phosphorylated in vivo in response to irradiation suggests a synergistic effect mediated by the two phosphorylations. Indeed, studies employing dual phosphorylation mimicking p53 mutants attest to this, demonstrating significantly reduced interaction with Mdm-2 and heightened transactivation of p21 and fas/APO-1 relative to single-site mutants (Jabbur and Zhang, 2002) . These findings are similar to the activation of MAP kinase Erk-2, in which dual phosphorylation of Thr183 and Tyr185 within the activation loop causes a conformational change of the activation loop and neighboring structures, resulting in enhanced substrate recognition and kinase activity (Canagarajah et al., 1997) .
In addition to Mdm-2 (Lin et al., 1994; Kussie et al., 1996) , the transactivation domain of p53 has been shown to interact with TAF II 31 (Lu and Levine, 1995; Thut et al., 1995) , the transcriptional co-activator CBP/ p300 Avantaggiati et al., 1997; Lill et al., 1997) and additional members of the transcription machinery, including TBP and TFIID (Seto et al., 1992; Chen et al., 1993; Liu et al., 1993; Mack et al., 1993; Martin et al., 1993; Truant et al., 1993) , and TFIIH (Xiao et al., 1994) . Moreover, studies have shown that the same amphipathic a-helical region of p53 involved in interacting with Mdm-2 also interacts with TAF II 31 (Uesugi and Verdine, 1999) , suggesting a blocking role for Mdm-2 in modulating the interaction of p53 with transcription factors.
Hydrogen bond disruption between Thr18 and Asp21 was observed to reduce the interaction of p53 with Mdm-2 and increase the transactivation function of p53. A simple scenario would be an enhancement of p53 binding to a transcription factor, such as TAF II 31, thereby facilitating the increased transactivation of downstream target genes p21 and Mdm-2. However, in contrast to the Mdm-2 pull-down assay results, equivalent binding to TAF II 31 was observed when TAF II 31 pull-down experiments were performed using wt, Thr18 or Asp21 GST-p53 fusion protein mutants (Figure 5c ). Although Mdm-2 and TAF II 31 bind to the same general region of p53, it is possible that different residues within this region of p53 may be critical for the interaction with Mdm-2 or TAF II 31, such that perturbation of a-helical structure caused by Thr18 phosphorylation may only effect Mdm-2 interaction. It is highly conceivable that phosphorylation at Ser20 may directly enhance the recruitment of TAF II 31 to p53. Crystallization of the p53/TAF II 31 complex, and subsequent structural analyses, will be required to resolve these issues. Second, the disruption of hydrogen bonding between Thr18 and Asp21 may not directly impact its interaction with TAF II 31. Rather, the disruption of hydrogen bonding may regulate the accessibility of p53 for TAF II 31, and possibly other transcription factors and/or co-activators, by attenuating its interaction with Mdm-2, thereby 'unmasking' the binding domain previously blocked by Mdm-2. This model is supported by our experiments in which GST-p53 fusion proteins were first incubated with Mdm-2 and then analysed for their binding to TAF II 31. The results demonstrated that the amount of TAF II 31 binding was inversely related to the amount of Mdm-2 pre-bound (Figure 5d ). In support of this finding, a similar observation was recently reported demonstrating that the in vitro interaction of CBP with p53 was abridged by prior interaction with Mdm-2 (Wadgaonkar and Collins, 1999) .
Understanding how the p53 tumor suppressor regulates cell proliferation in vivo requires a more comprehensive understanding of how p53 interaction with the transcriptional machinery is regulated. In the present work, we propose a generalized mechanism involved in the interaction of basal transcription factors and/or transcriptional co-activators with the p53 transactivation domain. Central to this mechanism is how the interaction between p53 and the transactivation repressor Mdm-2 is regulated, affecting the function of p53 by modulating its interaction with transcription factors and co-activators. Irradiation induced phosphorylation of p53 at Thr18 disrupts intramolecular hydrogen bonding and introduces charge repulsion between the amino acid residues Thr18 and Asp21. Disruption of this interaction, which may serve to de-stabilize the initiation and maintenance of the a-helical segment within the transactivation domain necessary for transactivation function, reduces the interaction of p53 with Mdm-2, indirectly enhancing the interaction of p53 with the transcription factor TAF II 31.
Materials and methods

p53 site-directed mutagenesis
The CMV-p53 expression vector (provided by Dr Bert Vogelstein of the Howard Hughes Medical Institute and the Johns Hopkins University) and the GST -p53 1-52 fusion construct (Uesugi and Verdine, 1999) were used as templates for generating p53 mutants. Mutations were introduced using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) using appropriate oligonucleotides according to the manufacturer's instructions. The oligonucleotide sense sequences (5'-3') are as follows, (mutated amino acid sequence underlined: Thr18?Ala18 (p53T18A), CCT CTG AGT CAG GAA GCA TTT TCA GAC CTA TG; Thr18?Asp18 (p53T18D), CCT CTG AGT CAG GAA GAT TTT TCA GAC CTA TG; Asp21?Ala21 (p53D21A), GAA ACA TTT TCA GCC CTA TGG AAA CTA C; Asp21?Asn21 (p53D21N), GAA ACA TTT TCA AAC CTA TGG AAA CTA C; Leu22, Trp23?Gln22, Ser23 (p53L22Q/W23S), CAT TTT CAG ACC AAT CGA AAC TAC TTC CTG AAA AC. Mutations were verified by sequencing (ABI prism).
Cell culture, irradiation and transfections K562 (p53 null) human erythroleukemia, BV173 (p53 wt) chronic myelogenous leukemia and ML-1 (p53 wt) myeloid leukemia cells were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum; LNCaP (p53 wt) human prostate carcinoma, MCF7 (p53 wt) human mammary carcinoma and 2KO (p53, Mdm-2 null) mouse fibroblast cells were maintained in Dulbecco's modified Eagle's medium/F12 supplemented with 10% fetal calf serum; A549 (p53 wt) human non-small lung carcinoma cells were maintained in HAM/F12 medium supplemented with 10% fetal calf serum and 1% glutamine. All cells were propagated in a 378C incubator containing 5% CO 2 . A549 cells were treated with 20 mM N-Acetyl-Leu-Leu-Norleucinal (Sigma) and harvested 3 h post-treatment. K562 (10 Gy), BV173 (10 Gy/30 J), ML-1 (10 Gy/30 J), LNCaP (7 Gy/50 J), MCF7 (10 Gy/30 J) and A549 (8 Gy/20 J) cells were irradiated with IR or UV and harvested 6 or 12 h posttreatment (respectively). For IR treatment, cells were exposed to 60 Co g-rays (United States Nuclear) at an approximate dose-rate of 4.5 Gy/min. For UV irradiation, cell monolayers (no media, washed with PBS) were exposed to an irradiator consisting of five UV bulbs delivering 254 nm (UV-C) of light at a dose rate of approximately 0.3 J/m 2 /s as measured by a photometer (IL 254; International Light, Inc.). Electroporation was used to transfect expression plasmids into K562 cells. Six million K562 cells were washed and resuspended in 450 ml of serum free RPMI 1640 media, incubated for 10 min with human p53 expression plasmid DNA at room temperature and subjected to electroporation in a 0.2 cm gap cuvette (Bio Rad) under the following conditions: T=500 V, C=600 mF, R=13 O, S=420 V (BTX, Inc.). Following 10 min recovery at room temperature, cells were maintained in 10 ml of RPMI 1640 media supplemented with 10% fetal calf serum until harvesting (24 h). FuGENE6 reagent (Boehringer Mannheim) was used to transfect 2KO cells, seeded to 35-mm plates 48 h before transfection, with 5 mg of human p53 expression plasmid DNA at a FuGENE6 : DNA ratio of 4 : 1. The transfection efficiency was approximately 40% for K562 cells and 15% for 2KO cells, as assessed by transfection with Green Fluorescent Protein expression plasmid DNA (pEGFP-C1, Promega).
Generation and evaluation of PAbThr18P antibody
PAbThr18P antibody was generated against an N-terminal phosphopeptide (Thr18P) of human p53 (NH 2 -S-Q-E-[pT]-F-S-D-L-W-K-COOH) by Quality Controlled Biochemicals. Antibody was isolated from crude serum and affinity-purified by a thiol-coupling gel linked to unphosphorylated peptide, followed by purification with phosphorylated peptide and elution in 100 mM glycine, pH 2.5 (Quality Controlled Biochemicals). Phosphopeptides used to demonstrate antibody specificity were generated by Quality Controlled Biochemicals. The peptide sequences are as follows: p53 Ser15P,
Western blotting, phosphatase treatment and immunoprecipitation analyses Total cellular protein extract was isolated from harvested cells on ice for 30 min using cold lysis buffer (20 mM Tris pH 7.6, 150 mM NaCl, 5 mM EDTA, 0.5% NP40, 10 mg leupeptin, 1 mM PMSF, 1 mM DTT) in the presence of 10 mM NaF and 12.5 mM sodium pyrophosphate (phosphatase inhibitors), with exception for phosphatase treated samples. Cellular debris was removed by centrifugation (14 000 r.p.m., 10 min, 48C). Immunoprecipitation of p53 was performed under non-reducing conditions (absence of DTT in lysis buffer) on a rotator for 4 h at 48C with 20 ml of protein-A agarose and 1 mg of anti-p53 antibody PAb421 (Ab-1, Oncogene Science). For phosphatase treatment, each protein sample on protein-A agarose was incubated with 66 DEA units of bovine intestinal alkaline phosphatase (Sigma) and 0.8 units of sweet potato acid phosphatase (Sigma) in 50 mM Tris buffer (pH 7.4) at 378C for 1 h. Non-immunoprecipitated extract or extract isolated from transfected cells was dissolved in SDS -PAGE loading buffer (250 mM Tris pH 6.8, 2% SDS, 4% b-mecaptoethanol, 10% glycerol), electrophoresized in a 5% stacking/10% running SDS -PAGE gel under reducing conditions, transferred to Hybond ECL membrane according to manufacturer's instructions (Amersham) and analysed utilizing antibodies against human p21
Waf1/Cip1 (CP74 hybridoma, provided by Wade Harper at Baylor College of Medicine), human Actin (Ab-1, Oncogene Science), human p53 (PAb1801, Oncogene Science), human Mdm-2 (2A10 hybridoma), mouse Tubulin (TU27B hybridoma) or mouse p21
Waf1/Cip1 (sc-397, Santa Cruz). Immunoprecipitated p53 samples were dissolved in SDS -PAGE loading buffer, electrophoresized under non-reducing conditions (absence of b-mecaptoethanol in SDS -PAGE loading buffer), transferred to Hybond ECL membrane and analysed using antibodies against human Thr18 phosphorylated p53 (PAbThr18P, Quality Controlled Biochemicals) or human p53 (DO1 or PAb1801, Oncogene Science) antibody. DO1 and PAb1801 antibodies recognize different, specific p53 epitopes. Under non-reducing conditions, the immunoprecipitating antibody PAb421 does not disassociate its heavy (52 -55 kDa) and light immunoglobulin chains, thus avoiding interference in detection of the p53 protein. Competition with respective peptide epitopes and PAbThr18P antibody entailed pre-incubation in hybridizing solution for 1 h at 48C. Protein expression was quantified applying chemiluminescent detection (ECL, Amersham) and emission capturing imagery with the EPI-Chemi Darkroom (UVP Laboratory Products). Fold induction of endogenous p21 protein was quantitated by plotting the expression of transfected p53 protein (x-ordinate) versus the expression of endogenous p21 protein (y-ordinate) for each transfected sample. For each set of plotted data, the highest level of p53 or p21 protein expression (x-or yordinate value) of any transfected sample was set to 100. Simple linear regression was applied to each incrementally transfected series, from which the fold induction of endogenous p21 protein, relative to wild-type p53 transfected (set to onefold), was calculated.
Northern blot analysis
Total cellular RNA was prepared using Triazol according to manufacturer's instructions (Life Technologies, Inc.), fractionated on a denaturing 1% formaldehyde-agarose gel, transferred by capillary action with 20X SSC buffer (Sigma) to Hybond N + nylon membrane (Amersham) and UV crosslinked at 120 000 mJ/cm 2 with a UV Stratalinker 1800 (Stratagene). Hybridizations were performed as described (Kobayashi et al., 1998 ) using a p21 probe radiolabeled with a-32 P deoxycytosine triphosphate (Amersham) generated by the random-primed DNA labeling kit and purified with a G-25 Sephadex column according to manufacturer's instructions (Boehringer Mannheim). The 2.1 kb NotI p21 cDNA fragment used to generate the radiolabeled probe was resolved by agarose gel electrophoresis and recovered with GeneClean II (Bio101). Expression of p21 was quantified using ImageQuant software and the Storm PhosphorImager 840 (Molecular Dynamics) and normalized to 28S rRNA expression resolved in the ethidium bromide stained formaldehyde-agarose gel.
Structural modeling of mutant p53 peptides
Wild-type and mutant p53 peptide (residues 17 through 29) structures bound to Mdm-2 oncoprotein were modeled based on the X-ray coordinates of the complex between the Nterminal p53 binding domain of Mdm-2 and a peptide from the transactivation domain of human p53 (Kussie et al., 1996) using Swiss-Model (Guex et al., 1999) or Insight II 97.0 program and the Discover simulation package (Molecular Simulations Inc.). Ribbon diagrams corresponding to the Mdm-2/p53 peptide structural models were drawn by Insight II.
Protein purification and in vitro interaction assays GST-p53 1-52 was generated as described (Uesugi et al., 1997) and transformed into BL-21 cells according to manufacturer's instructions (Gibco BRL). Transformed cells were grown at 308C to an OD 600 of 0.5 in 200 ml of Luria Broth supplemented with Ampicillin. The culture was then induced with 0.4 mM isopropyl b-D-thiogalactopyranoside and harvested 5 h later. Cells were resuspended in buffer (PBS, 1% Triton-X), sonicated in triplicate at 4 watts for 5 s (Fisher) and incubated, rocking on ice, for 30 min. After clearing cellular debris by centrifugation, the supernatant was incubated for 30 min with rocking at 48C with glutathionesepharose 4B beads (Pharmacia) and washed in triplicate with PBS. TAF II 31 1-140 was expressed and purified as described (Uesugi et al., 1997) ; full-length Mdm-2 was in vitro translated and transcribed (Promega) in the presence of 35 S-methionine (Amersham). For the interaction with TAF II 31 1-140 , GST -p53 1-52 fusion beads (loaded with 200 mg of protein) were incubated with 50 mg of TAF II 31 1-140 in 200 ml of binding buffer (20 mM Tris pH 7.4, 50 mM NaCl, 2 mM DTT, 10 mM MgCl 2 , 0.02% NP-40, 10% glycerol) at 48C for 1 h and washed in triplicate in binding buffer. Samples were dissolved in SDS -PAGE loading buffer and electrophoresized in a 5% stacking/15% running gel under reducing conditions, followed by detection with Coomassie stain. For the interaction with Mdm-2, 20 ml of in vitro transcribed/translated Mdm-2 was applied, using binding buffer containing 150 mM NaCl.
